Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma
Clinical trial NCT04234061 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04234061
- Sponsor
- Peter MacCallum Cancer Centre, Australia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-07
- Primary completion
- 2027-09-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.